rrx-001 and Reperfusion-Injury

RRx-001, a clinical macrophage-stimulating anti-cancer agent that also produces nitric oxide (NO) was studied in a model of ischemia-reperfusion injury.. The results demonstrated that, compared to control, RRx-001 preconditioning increased blood flow and functional capillary density, and preserved tissue viability in the absence of side effects over a sustained time period.. Thus, RRx-001 may serve as a long-lived protective agent during postsurgical restoration of flow and other ischemia-reperfusion associated conditions, increasing blood flow and functional capillary density as well as preserving tissue viability in the absence of side effects.

Topics: Animals; Azetidines; Blood Flow Velocity; Capillaries; Cricetinae; Disease Models, Animal; Male; Mesocricetus; Microcirculation; Nitro Compounds; Reperfusion Injury; Sodium Nitrite